Cyrille Chery

Cyrille Chery

Auto-generated profile, based on publicly available information

Cyrille Chery

UCB, Analytical Development Sciences for Biologicals, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

21 August 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

31 March 2023 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
SHSteve Hessmann
Steve Hessmann
CCCyrille Chery
Cyrille Chery
ASAnne-Sophie Sikora
Anne-Sophie Sikora
AGAnnick Gervais
Annick Gervais
CCChristine Carapito
Christine Carapito
Monitoring of host cell proteins (HCPs) during the manufacturing of monoclonal antibodies (mAb) has become a critical requirement to provide effective and safe drug products. Enzyme-linked immunosorbent assays are still the gold standard methods for the quantification of protein impurities. However, this technique has several limitations and does, among others, not enable the precise identification of proteins. In this context, mass spectrometry (MS) became an alternative and orthogonal method that delivers qualitative and quantitative information on all identified HCPs. However, in order to be routinely implemented in biopharmaceutical companies, liquid chromatography-MS based methods still need to be standardized to provide highest sensitivity and robust and accurate quantification. Here, we present a promising MS-based analytical workflow coupling the use of an innovative quantification standard, the HCP Profiler solution, with a spectral library-based data-independent acquisition (DIA) method and strict data validation criteria. The performances of the HCP Profiler solution were compared to more conventional standard protein spikes and the DIA approach was benchmarked against a classical data-dependent acquisition on a series of samples produced at various stages of the manufacturing process. While we also explored spectral library-free DIA interpretation, the spectral library-based approach still showed highest accuracy and reproducibility (coefficients of variation < 10%) with a sensitivity down to the sub-ng/mg mAb level. Thus, this workflow is today mature to be used as a robust and straightforward method to support mAb manufacturing process developments and drug products quality control.

17 January 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
FNFelix Nikels
Felix Nikels
PGPatrick Garidel
Patrick Garidel
KBKaroline Bechtold-Peters
Karoline Bechtold-Peters
SGSanjay Gupta
Sanjay Gupta
SBStefan Bleher
Stefan Bleher